Why It Matters

1Day Sooner Action Project Inc., a nonprofit focused on pandemic preparedness and Food and Drug Administration (FDA) reform, terminated its engagement with lobbying firm Tenagrity Solutions LLC on July 25, according to an LDA termination filing.

By The Numbers

The filing disclosed $10,000 in income.

The firm earned $180,000 total from 1Day Sooner across the roughly two-year engagement, with quarterly payments ranging from $10,000 to $30,000.

The nonprofit has received approximately $11.3 million in cumulative funding since its March 2020 founding through December 2024, and notably takes no money from pharmaceutical companies, vaccine manufacturers, or germicidal UV technology firms—the industries that might benefit most from its advocacy priorities.

Broader Context

The organization is a 501(c)(4) social welfare organization that aims to reduce the global burden of infectious disease and avert future pandemics by accelerating the development and implementation of vaccines, treatments, and mechanical interventions, works on FDA reform including AI-assisted transparency and improved use of the FDA's Sentinel system, and advocates for improved indoor air quality including germicidal UV light technology in federal and military facilities. Its lobbying agenda touched six distinct policy areas: health issues, medical research, defense, budget and appropriations, Medicare and Medicaid, and clean air and water.

Pandemic and All-Hazards Preparedness's (PAHPA) core authorizations expired in September 2023, and Congress provided only a short-term extension through September 30, 2025 via P.L. 119-4. As of August 7, 2025, a full reauthorization has not been enacted. A bipartisan reauthorization was included in the American Relief Act, 2025 (H.R. 10515), but that bill did not pass.

Tenagrity lobbied on the Prescription Drug User Fee Act (PDUFA), which was reauthorized through fiscal year 2027 when President Biden signed the FDA User Fee Reauthorization Act of 2022 on September 30, 2022. However, the FDA issued a Federal Register notice in May 2025 beginning the public process for the next PDUFA reauthorization cycle covering fiscal years 2028 through 2032, which remains pending.

The 2025 U.S. Health and Human Services (HHS) reorganization cut approximately 20,000 positions, with the FDA losing roughly 3,500 staff. In March 2025, $11.4 billion in COVID-19 pandemic preparedness funds were clawed back from the CDC to state and local health departments. Fiscal year 2026 appropriations were not enacted in regular order, forcing the government to operate under continuing resolutions.

In its final filing, Tenagrity noted that 1Day Sooner was still actively lobbying on indoor air quality, FDA reforms involving artificial intelligence and the FDA's Sentinel system, human challenge studies, and FY27 National Defense Authorization Act and appropriations. The firm worked with offices of Reps. Auchincloss (D-MA), Cline (R-VA), Griffith (R-VA), and Harder (D-CA), as well as Sen. Hickenlooper (D-CO), on legislation drafting and related advocacy.

The Bottom Line

Caroline DeBerry was the primary lobbyist for Tenagrity Solutions LLC on the 1Day Sooner Action Project Inc. account.

***

Access the Legis1 platform for comprehensive political news, data, and insights.

---

Spot something wrong? Report an issue with this article